A Prospective Study Evaluating Cumulative Incidence and a Specific Prediction Rule in Pulmonary Embolism in COVID-19

Carla Suarez Castillejo1,2, Nuria Toledo-Pons1,2, Néstor Calvo3, Luisa Ramon-Clar1,2, Joaquin Martinez1,2, Sara Hermoso de Mendoza4, Daniel Morell-Garcia2,5, Josep Miquel Bauça5, Francisco Berga5, Belén Nuñez1,2, Luminina Preda5, Jaume Sauleda1,2,6, Paula Argente Castillo5, Antonieta Ballesteros5, Luisa Martin7, Ernest Sala-Llinas1,2,6 and Alberto Alonso-Fernández1,2,6

1 Servicio de Neumología, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 2 Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma, Spain, 3 Servicio de Radiodiagnostic, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 4 Complejo Hospitalario de Navarra, Pamplona, Spain, 5 Servicio de Análisis Clínicos, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 6 CIBER Enfermedades Respiratorias, Palma de Mallorca, Spain, 7 Servicio de Medicina Interna, Hospital Universitario Son Espases, Palma de Mallorca, Spain

Rationale: Abnormal values of hypercoagulability biomarkers, such as D-dimer, have been described in Coronavirus Disease 2019 (COVID-19), which has also been associated with disease severity and in-hospital mortality. COVID-19 patients with pneumonia are at greater risk of pulmonary embolism (PE). However, the real incidence of PE is not yet clear, since studies have been limited in size, mostly retrospective, and PE diagnostic procedures were only performed when PE was clinically suspected.

Objectives: (1) To determine the incidence, clinical, radiological, and biological characteristics, and clinical outcomes of PE among patients hospitalized for COVID-19 pneumonia with D-dimer > 1,000 ng/mL. (2) To develop a prognostic model to predict PE in these patients.

Methods: Single-center prospective cohort study. Consecutive confirmed cases of COVID-19 pneumonia with D-dimer > 1,000 ng/mL underwent computed tomography pulmonary angiography (CTPA). Demographic and laboratory data, comorbidities, CTPA scores, treatments administered, and clinical outcomes were analyzed and compared between patients with and without PE. A risk score was constructed from all these variables.

Results: Between 6 April 2020 and 2 February 2021, 179 consecutive patients were included. The overall incidence of PE was 39.7% (71 patients) (CI 95%, 32–47%). In patients with PE, emboli were located mainly in segmental/subsegmental arteries (67%). Patients with PE did not differ from the non-PE group in sex, age, or risk factors for thromboembolic disease. Higher urea, D-Dimer, D-dimer-to-ferritin and D-dimer-to-lactate dehydrogenase (LDH) ratios, platelet distribution width (PDW), and neutrophil-to-lymphocyte ratio (NLR) values were found in patients with PE when...
Suarez Castillejo et al. Pulmonary Embolism in COVID-19 Pneumonia

rates are higher when D-dimer is > certain underlying medical comorbidities (1, 2). Further, fatality from 0.15 to 5%, and substantial variability by location and respiratory distress syndrome, with mortality rates ranging clinical features, from asymptomatic infection to acute syndrome coronavirus-2 (SARS-CoV-2) presents heterogeneous The disease caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) presents heterogeneous clinical features, from asymptomatic infection to acute respiratory distress syndrome, with mortality rates ranging from 0.15 to 5%, and substantial variability by location and certain underlying medical comorbidities (1, 2). Further, fatality rates are higher when D-dimer is > 1,000 ng/mL among hospitalized patients and increase exponentially with age (2–5). Likewise, severe Coronavirus Disease-19 (COVID-19) may show systemic hyper-inflammation (6) and complex coagulation abnormalities that generate a hypercoagulable state (5). Previous studies suggest a possible association between COVID-19 and pulmonary embolism (PE) (7–12). Some risk factors for severe COVID-19 and death, including obesity, increasing age, and a hypercoagulable state, are the same as those for PE. Moreover, patients with COVID-19 are usually bedridden for many days during the acute phase. Rates of PE complications in COVID-19 are low in non-hospitalized patients with asymptomatic or mild diseases but higher with increasing severity of the infection, with those in the intensive care unit (ICU) being at the greatest risk (13, 14). Furthermore, PE has been associated with higher mortality rates (8, 13), and recent data suggest that intermediate-dose thromboprophylaxis is not superior to standard thromboprophylaxis in critically ill patients (14). Nevertheless, elsewhere, a much lower incidence of PE was found among hospitalized patients with COVID-19 (15, 16).

Although the etiopathogenesis of PE in COVID-19 is poorly understood, factors related to the acute inflammatory response to the disease may be contributing to a dysregulation of the equilibrium of procoagulant and anticoagulant mechanisms (2, 6, 17). Pulmonary embolism diagnosis is a challenging task in COVID-19 hospitalized patients, mainly due to its non-specific clinical presentation and also because symptoms of PE overlap with COVID-19. Nevertheless, early PE diagnosis is essential, as well-timed treatment is highly effective and proven to significantly influence clinical outcomes (18). D-dimer values > 1,000 ng/mL are relatively common in patients with COVID-19, ranging from 40 to 70% (5, 19), with a more pronounced increase among severe cases (3, 20).

In a preliminary study, we prospectively evaluated the incidence of PE in 30 hospitalized patients with COVID-19 pneumonia and D-dimer > 1,000 ng/mL and found an incidence of 50%, regardless of clinical suspicion (12). However, this incidence may have been conditioned by the limited sample size. Additionally, other studies that analyzed the incidence of PE in COVID-19 were of a retrospective nature; diagnostic procedures were only performed when thrombotic complications were suspected, so the reported incidence may not be considered definitive either (7, 8, 21–25). Overall, all the above seem to indicate that high D-dimer values are common in patients with severe forms of COVID-19 and, as such, it is, therefore, reasonable to believe that patients with COVID-19 are at high risk of PE. Accordingly, we aimed to prospectively evaluate the incidence of PE in patients admitted with COVID-19 pneumonia and D-dimer > 1,000 ng/mL, regardless of clinical suspicion. As secondary objectives, we evaluated clinical, radiological, and biochemical variables that could be potentially related to this event; determined whether patients with PE had worse clinical outcomes; and developed a prognostic model to predict PE in this cohort of hospitalized patients with COVID-19.

**INTRODUCTION**

**MATERIALS AND METHODS**

**Study Design and Participants**

A single-center prospective cohort study was performed (Hospital Universitari Son Espases, Palma, Spain). All consecutive adult patients with confirmed COVID-19 pneumonia admitted to the hospital and with at least one D-dimer measurement > 1,000 ng/mL during hospitalization were selected. COVID-19 was confirmed by a positive result on polymerase chain reaction (PCR) testing of a nasopharyngeal sample.

Patients were excluded if they were on anticoagulant treatment for 3 months before admission or were unable to undergo a

**Conclusion:** COVID-19 patients with pneumonia and D-dimer values > 1,000 ng/mL were presented with a very high incidence of PE, regardless of clinical suspicion. Significant differences in urea, D-dimer, PDW, NLR, and lymphocyte count were found between patients with PE and non-PE. The PATCOM score is presented in this study as a promising PE prediction rule, although validation in further studies is required.

Keywords: computed tomography angiography, coronavirus infections, fibrin fibrinogen degradation products, pandemics, SARS-CoV-2, venous thromboembolism, clinical decision rule

**KEYWORDS:** Pulmonary Artery Thrombosis

- Computed tomography angiography
- Coronavirus infections
- Fibrin fibrinogen degradation products
- Pandemics
- SARS-CoV-2
- Venous thromboembolism
- Clinical decision rule
computed tomography pulmonary angiography (CTPA) for any of the following reasons: unwillingness or inability to participate in the study; allergy to iodinated contrast; or any other concurrent clinical condition which, in the researcher's opinion, would contraindicate their participation in the study.

All patients were followed up throughout the hospital admission period until hospital discharge or death. The strengthening the reporting of observational studies in epidemiology (STROBE) statement was followed (26).

The sample size was calculated to analyze the estimated incidence of PE in hospitalized patients because of COVID-19 pneumonia with a D-dimer value > 1,000 ng/mL in a previous study, revealing a 50% incidence of PE (12). Assuming a calculation error of 3% and a confidence level of 90%, 179 patients with a valid CTPA scan were needed. The study was completed when the sample size was reached.

**Description of Investigations Undertaken**

Epidemiological, demographic, clinical, and laboratory examinations were collected from all subjects at the time of admission. The data recorded included time from symptom onset to hospital admission and to CTPA, medical treatment during hospitalization, thromboprophylaxis, respiratory support, clinical outcomes (acute respiratory failure, arrhythmia, ICU admission, or death), and strong-moderate PE risk factors. The CURB-65 score was calculated (27).

Laboratory data included complete blood count (Cell-Dyn Sapphire platform, Abbott Diagnostics, United States), coagulation, and kidney and liver function tests collected upon admission. In addition, baseline, peak, and prior-to-CTPA values of the following biomarkers were analyzed in each patient: fibrinogen, D-dimer (reported as D-dimer units), C-reactive protein (CRP), lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), and ferritin. In addition, high sensitive troponin I, interleukin-6 (IL-6), interleukin-10 (IL-10) (ELISA, R&D systems), N-terminal pro hormone B-type natriuretic peptide (NT pro-BNP) (Test 1 THL Module, ALI FAX; Architect platform, Abbott Diagnostics), and fibrinogen were also measured. Blood gas analyses were performed on the GEM 4000 platform (Werfen, Spain). D-dimer-to-ferritin, D-dimer-to-LDH, and D-dimer-to-CRP ratios were calculated.

**Computed Tomography Pulmonary Angiography**

Computed tomography pulmonary angiography was requested per protocol only when the D-dimer determination was > 1,000 ng/mL, regardless of symptoms. Diagnosis of PE was performed by an expert radiologist based on direct visualization of the endoluminal thrombus in the pulmonary arteries. A quantitative assessment of the magnitude of the embolism was calculated with the pulmonary artery obstruction index (PAOI) (28). COVID-19 total lung involvement was automatically calculated by artificial intelligence analysis performed using InferRead™ CT Lung (COVID-19) (Infervision, Europe GmbH, Germany) (29). The right ventricle to left ventricle diameter ratio (RV/LV) was measured as an indicator of RV dysfunction (18).

**Ethics Statement**

The Institutional Ethics Committee of the Balearic Islands approved the study (IB 4197/20 PI), and all subjects gave their written informed consent. Only patients with a critical clinical condition gave verbal consent instead, in front of at least two witnesses.

**Statistical Analysis**

Descriptive statistics included frequencies and percentages for categorical variables and medians and interquartile ranges (IQRs) for continuous variables. Comparisons were determined by the Mann-Whitney U-test for continuous variables, and by the χ²-test or Fisher’s exact test for categorical variables. Spearman’s correlation was used to assess relationships between PAO1 and biomarkers.

The total population of the study was divided into two groups: patients who either did not require ICU-level care or underwent CTPA before their ICU admission (Group A) and ICU patients who underwent CTPA during or after ICU admission (Group B). Baseline variables related to the presence of PE in the regression analysis were dichotomized to construct predictive scores for PE with patients from Group A. Youden’s index criteria were used to determine the cut-off point for each variable. After dichotomization, these variables were included in a logistic regression model. The beta coefficient of each variable was divided by the smallest absolute value of the regression coefficient and rounded to the nearest integer to calculate the relative weight of each variable. The sum of the relative weight of all the variables included in the score corresponded to its total value. The discriminatory capacity of the score was evaluated by a receiver operating characteristic (ROC) curve analysis, and the sensitivity, specificity, and positive and negative predictive values of different cut-off points were calculated. The calibration and overall performance of the model were evaluated using the Hosmer-Lemeshow goodness-of-fit test (HL) and the Nagelkerke R² score, respectively. Differences were considered statistically significant at a 2-tailed p-value of < 0.05. The statistical software used was SPSS v.26 (IBM Corporation, United States).

**RESULTS**

**COVID-19 Pneumonia Population**

A total of 1,798 patients with COVID-19 were hospitalized during the study period (6 April 2020 to 2 February 2021). Overall, 324 of those patients had pneumonia with D-dimer > 1,000 ng/mL during hospitalization, and 142 of them presented at least one exclusion criterion. Ultimately, CTPA was performed on 182 patients, three of whom were excluded due to invalid CTPA (Figure 1).

In total, 179 patients were included in the analysis. Anthropometric and clinical characteristics are described in Table 1. The median age was 64.5 (55–74) years, and 66.5% of patients were men. The median time from symptom onset to
hospital admission was 8 (4–10) days. The median CURB-65 score was 1 in the emergency department. Totally, 61 patients (34.3%) were admitted to the ICU.

Most patients were on thromboprophylaxis with enoxaparin (154 with 40 mg per day and 20 with at least 1 mg/kg daily) before CTPA. The remaining five subjects were not on thromboprophylaxis before CTPA.

Pulmonary Embolism Incidence Among COVID-19 Patients With Pneumonia

The overall incidence of PE was 39.7% (CI 95%, 32.4–47%). There were more patients with previous cardiovascular disease in the PE group when compared with those without. No significant differences were found in PE incidence according to age, sex, obesity, ICU admission, or type of specific treatment (hydroxychloroquine, remdesivir, tocilizumab, or systemic steroids) (Supplementary Table 1).

Totally, 20 patients presented at least one strong-moderate risk factor for PE (9 in the PE group and 11 in the non-PE group). Even when excluded from the analysis, the incidence of PE in the remaining population was still 39%.

There was a median 19-day interval between time from hospital admission and CTPA in Group B (n = 58), which was significantly longer than in the 121 patients in Group A (1; CI: 0–7 days). Furthermore, significant clinical and relevant differences were found between groups (Supplementary Tables 2–4).

Comparison Between Patients With Pulmonary Embolism and Non-pulmonary Embolism

Age, sex, anthropometric, and clinical characteristics, physical examination, PE risk factors, and treatment during hospitalization were not significantly different between PE and non-PE individuals (Table 1). Moreover, no differences were found in the time from admission to CTPA [6.5 (1–19) vs. 7 (0–13) days, respectively].

Patients with PE required higher fractional inspired oxygen (FiO₂), but no differences were found in the number of subjects requiring invasive/non-invasive ventilatory support or oxygen by high flow nasal cannula (Table 1). In addition, pharmacological therapy was similar during hospitalization (Table 1).
| TABLE 1 | Baseline anthropometric and clinical characteristics of patients admitted because of COVID-19 pneumonia (all patients) and according to outcome (with and without pulmonary embolism). |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| All patients (n = 179) | Non-PE patients (n = 108) | PE patients (n = 71) | P-value |
| Age, yrs. | 64 (55–74) | 63 (54–74) | 65 (55–73) | 0.79 |
| Sex, male, n (%) | 119 (66.5) | 67 (62.0) | 52 (73.2) | 0.12 |
| Body mass index, Kg/m² | 28.8 (25.8–31.6) | 28.5 (25.1–31.7) | 29.6 (26.3–31.6) | 0.18 |
| Cardiovascular disease, n (%) | 28 (15.6) | 12 (11.1) | 16 (22.5) | 0.04 |
| Arrhythmia, n (%) | 8 (4.5) | 6 (5.6) | 2 (2.8) | 0.48 |
| Chronic respiratory disease, n (%) | 19 (10.6) | 12 (11.1) | 7 (9.9) | 0.79 |
| Previous antiplatelet treatment, n (%) | 30 (16.8) | 21 (15.4) | 9 (12.7) | 0.24 |
| Time from symptom onset to hospital admission, days | 8 (4–10) | 8 (4–10) | 7 (4–11) | 0.52 |
| Time from symptom onset to CTPA, days | 15 (10–24) | 15 (9–26) | 15 (10–22) | 0.79 |
| Current or former smokers, n (%) | 67 (37.4) | 41 (38.0) | 26 (36.6) | 0.86 |
| Smoking, Pack-year | 0 (0–10) | 0 (0–15) | 0 (0–10) | 0.90 |
| Symptoms | | | | |
| Cough, n (%) | 132 (74.2) | 78 (72.2) | 54 (77.1) | 0.46 |
| Fever, n (%) | 125 (69.8) | 73 (67.6) | 52 (73.2) | 0.42 |
| Dyspnea, n (%) | 106 (59.2) | 65 (60.2) | 41 (57.7) | 0.75 |
| Hemoptysis, n (%) | 1 (0.6) | 0 (0.0) | 1 (1.4) | 0.40 |
| Chest pain, n (%) | 11 (6.1) | 5 (4.6) | 6 (8.5) | 0.35 |
| Physical examination | | | | |
| Respiratory rate, breaths per min | 22 (20–27) | 24 (18–28) | 22 (20–26) | 0.92 |
| Heart rate, beats per min | 87 (75–102) | 87 (75–99) | 86 (74–104) | 0.77 |
| Systolic BP, mm Hg | 126 (114–137) | 125 (113–138) | 126 (117–135) | 0.62 |
| Diastolic BP, mm Hg | 70 (62–79) | 70 (60–78) | 72 (63–80) | 0.36 |
| Temperature, °C | 36.8 (36.1–37.6) | 36.8 (36.1–37.6) | 36.9 (36.1–37.6) | 0.86 |
| Lower limb edema, n (%) | 171 (95.5) | 103 (95.4) | 68 (95.8) | 1 |
| CURB 65 | 1 (0–2) | 1 (0–2) | 1 (1–2) | 0.54 |
| Strong-moderate PE risk factors | | | | |
| Heart failure, n (%) | 3 (1.7) | 0 (0) | 3 (4.2) | 0.06 |
| Fracture of lower limb | 1 (0.6) | 1 (0.9) | 0 (0.0) | 1 |
| Chronic respiratory failure, n (%) | 2 (1.1) | 1 (0.9) | 1 (1.4) | 1 |
| Neoplasm, n (%) | 13 (7.3) | 9 (8.3) | 4 (5.6) | 0.50 |
| Previous VTE, n (%) | 1 (0.6) | 0 (0.0) | 1 (1.4) | 0.40 |
| Myocardial infarction (within previous 3 months), n (%) | 1 (0.6) | 0 (0) | 1 (1.4) | 0.22 |
| One or more known risk factors for PE, n (%) | 20 (11.2) | 11 (10.2) | 9 (12.7) | 0.61 |
| Treatment in hospital | | | | |
| Oxygen therapy | | | | |
| Maximum FiO₂ | 1.0 (0.3–1.0) | 0.5 (0.3–1.0) | 1.0 (0.4–1.0) | 0.00 |
| HFNC, n (%) | 43 (24.2) | 24 (22.4) | 19 (26.8) | 0.51 |
| NIV, n (%) | 5 (2.8) | 3 (2.8) | 2 (2.8) | 1 |
| IMV, n (%) | 61 (34.3) | 36 (33.6) | 25 (35.2) | 0.83 |
| Pharmacological therapy | | | | |
| Azithromycin, n (%) | 28 (15.6) | 18 (16.7) | 10 (14.1) | 0.64 |
| Hydroxychloroquine, n (%) | 36 (20.1) | 18 (16.7) | 18 (16.7) | 0.16 |
| Remdesivir, n (%) | 27 (15.2) | 18 (16.8) | 9 (12.7) | 0.45 |
| Tocilizumab, n (%) | 40 (22.3) | 20 (18.5) | 20 (28.2) | 0.13 |
| Other biological therapy, n (%) | 7 (3.9) | 3 (2.8) | 4 (5.6) | 0.44 |
| Systemic steroids, n (%) | 180 (99.4) | 96 (88.9) | 64 (90.1) | 0.79 |
| Clinical outcomes | 17 (56.7) | 9 (60.0) | 8 (53.3) | 0.71 |
| Acute respiratory failure, n (%) | 126 (73.7) | 74 (71.8) | 52 (76.5) | 0.50 |
| Arrhythmia, n (%) | 3 (1.7) | 1 (0.9) | 2 (2.8) | 0.56 |
| ICU admission, n (%) | 74 (41.3) | 40 (37.0) | 34 (47.9) | 0.15 |
| Death, n (%) | 10 (5.6) | 4 (3.7) | 6 (8.5) | 0.20 |

Values represent percentage or median (IQR) according to its distribution. CTPA, computed tomography pulmonary angiography; BP, blood pressure; PE, pulmonary embolism; VTE, Venous thromboembolism; IVF, in vitro fertilization; FiO₂, fractional inspired oxygen; HFNC, High Flow Nasal Cannula; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation; ICU, intensive care unit. Bold indicates statistically significant differences between the groups.
In total, 10 patients died during hospitalization (4 non-PE vs. 6 PE, \( p = 0.20 \)). The main cause of death was respiratory failure. The time from admission to death was 17 days (10–33), with no significant differences between the two groups. Eight patients were readmitted in the follow-up, 50% of them in the PE group. No differences in ICU admission, acute respiratory failure, or arrhythmia were found between both groups during hospitalization (Table 1).

### Radiological Findings

The total lung involvement of COVID-19 was 16.7% in all patients. No differences were detected between the two groups [PE 19.9% (4.6–35.2)]; non-PE 15.5% (4.1–31); \( p = 0.75 \)]. PE showed a predominantly peripheral distribution, affecting at least one lobar, segmental, or subsegmental artery to 31, 42.3, and 26.8%, respectively. The overall PAOI and RV/LV ratios were 10% (5–22.5) and 0.9 (0.9–1.0), respectively. No difference in RV/LV ratio was found between groups.

### Laboratory Findings

Baseline laboratory findings, inflammatory, and PE biomarkers are shown in Tables 2, 3. Patients with PE showed higher neutrophil count and urea values when compared to patients with non-PE (\( p < 0.05 \)). However, there were no significant differences in baseline coagulation function or arterial blood gas tests.

Higher baseline, peak and prior-to-CTPA D-Dimer, D-dimer-to-ferritin and D-dimer-to-LDH ratios, platelet distribution width (PDW), and neutrophil-to-lymphocyte ratio (NLR) values were found in patients with PE when compared to patients with non-PE (\( p < 0.05 \) all variables). Moreover, baseline, minimum, and prior-to-CTPA lymphocyte counts were found to be lower in patients with PE, while no differences were detected in platelet count, ESR, CRP, LDH, ferritin, IL-6, NT-proBNP, troponin, or fibrinogen values. In contrast, IL-10 concentration was lower in patients with PE (Table 3).

In patients with PE, bivariate analysis revealed significant correlations between the PAOI and baseline (rho = 0.24, \( p = 0.045 \)), prior to CTPA (rho = 0.25, \( p = 0.04 \)), peak (rho = 0.27, \( p = 0.02 \)) D-dimer values, D-dimer-to-LDH ratio (rho = 0.28, \( p = 0.04 \)) on admission, and peak IL-10 levels (rho = −0.31, \( p = 0.03 \)).

### Pulmonary Embolism Predictive Score

A total of 11 variables related to the presence of PE in the regression analysis were dichotomized in order to construct a PE predictive score with Group A patients. After dichotomization, multivariable logistic regression analysis led to a selection of four variables (Supplementary Table 5). Table 4 shows the constructed prediction score with the calculated weight and cut-off points of the variables. The PATCOM score stands for Pulmonary Artery Thrombosis in COVID-19 Mallorca and included the platelet count, PDW, urea concentration, and D-dimer-to-ferritin ratio. The AUC-ROC of the PATCOM score was 0.81 (95% CI: 0.73–0.89). The suggested score ranged from

---

**TABLE 2 | Baseline laboratory data.**

| Blood count, baseline | All patients \((n = 179)\) | Non-PE patients \((n = 108)\) | PE patients \((n = 71)\) | \(P\)-value |
|-----------------------|-----------------|-----------------|-----------------|----------------|
| Hemoglobin, g/dL      | 13.6 (12.3–14.9) | 13.5 (12–14.9)  | 13.7 (12.7–15)  | 0.19           |
| Leucocyte count, 10\(^9\)/\(\mu\)L | 8.0 (5.5–11.4) | 7.6 (5.4–10.1)  | 8.6 (5.6–12.0)  | 0.08           |
| Neutrophils, \%       | 78.4 (70.8–84.8) | 76.1 (69.4–84.4) | 81.3 (74.8–85.1) | 0.04           |
| Biochemical profile, baseline |                |                 |                 |                |
| Glucose, mg/dL        | 125 (105–156)   | 121 (105–146)   | 136 (111–167)   | 0.08           |
| ALT, U/L              | 29 (17–54)      | 26 (17–64)      | 34 (21–48)      | 0.6            |
| Urea, mg/dL           | 35 (26–51)      | 33 (24–47)      | 40 (31–54)      | 0.04           |
| Creatinine, mg/dL     | 0.8 (0.7–1.1)   | 0.8 (0.7–1.1)   | 0.9 (0.8–1.2)   | 0.06           |
| Sodium, mEq/L         | 137 (135–140)   | 138 (135.5–140) | 137 (135–140)   | 0.43           |
| Potassium, mEq/L      | 4.1 (3.7–4.6)   | 4.0 (3.7–4.6)   | 4.1 (3.8–4.6)   | 0.34           |
| Procalcitonin, ng/mL  | 64.5 (60–68.1)  | 64.8 (60.7–67.7) | 64.4 (61.0–68.7) | 0.94           |
| Cholesterol, mg/dL    | 147 (119–172)   | 141 (121–168)   | 149 (116–183)   | 0.26           |
| Triglyceride, mg/dL   | 135 (103–191)   | 128 (86–180)    | 151 (111–199)   | 0.12           |
| Coagulation function, baseline |                |                 |                 |                |
| PT, %                 | 81 (69–88)      | 81.5 (72–89)    | 79 (66–86)      | 0.10           |
| INR                   | 1.1 (1.1–1.3)   | 1.1 (1.1–1.2)   | 1.1 (1.1–1.3)   | 0.28           |
| Fibrinogen, mg/dL     | 872 (729–1,050) | 881 (719–1,052) | 884 (744–1,050) | 0.94           |
| Arterial blood test, baseline |                |                 |                 |                |
| PaO\(_2\)/FiO\(_2\)\ ratio | 276 (220–324) | 286 (233–324) | 262 (214–324) | 0.14           |
| pH                    | 7.46 (7.43–7.49) | 7.46 (7.43–7.50) | 7.46 (7.44–7.49) | 0.74           |
| PaO\(_2\), mmHg        | 62.5 (54.0–74.5) | 63.0 (54.0–72.0) | 62.0 (53.0–76.0) | 0.74           |
| PaCO\(_2\), mmHg       | 32.0 (29.0–36.0) | 33.0 (30.0–36.0) | 31.0 (28.0–35.0) | 0.24           |

Values represent median (IQR). ALT, alanine aminotransferase; PT, prothrombin time; PaO\(_2\), partial pressure of arterial blood oxygen; FiO\(_2\), fractional inspired oxygen; PaCO\(_2\), partial pressure of arterial blood carbon dioxide. Bold indicates statistically significant differences between the groups.
### TABLE 3 | Inflammatory profile and pulmonary embolism biomarkers of patients admitted because of COVID-19 pneumonia with and without pulmonary embolism.

|                  | All patients  | Non-PE patients | PE patients | P-value |
|------------------|---------------|-----------------|-------------|---------|
|                  | (n = 179)     | (n = 108)       | (n = 71)    |         |
| LDH, U/L         |               |                 |             |         |
| Baseline         | 357 (283–498) | 359 (284–528)   | 351 (281–488) | 0.85    |
| Peak             | 451 (340–611) | 455.5 (337–626) | 435 (340–590) | 0.72    |
| Prior to CTPA    | 345 (277–439) | 324 (270–432)   | 351 (288–439) | 0.49    |
| CRP, mg/dL       |               |                 |             |         |
| Baseline         | 10.2 (4.4–19.2)| 9.7 (4.4–19.2)  | 10.9 (4.3–20.8) | 0.59    |
| Peak             | 15 (7.6–24.6) | 14 (6.8–22.8)   | 16.2 (8.5–26.5) | 0.25    |
| Prior to CTPA    | 5.2 (1.5–13.3)| 4.4 (1.3–11.5)  | 5.8 (1.7–15.4) | 0.23    |
| ESR, mm/h        |               |                 |             |         |
| Baseline         | 69 (45–89)    | 69 (45–89)      | 70 (45.5–90)  | 0.81    |
| Peak             | 77 (61–103)   | 77 (57–104)     | 76 (65–94)   | 0.98    |
| Prior to CTPA    | 59 (35–85)    | 59 (35–85)      | 58 (34–81)   | 0.91    |
| D-dimer, ng/mL   |               |                 |             |         |
| Baseline         | 848 (294–2,329)| 689 (256–1,672) | 1,039 (324–4,888) | 0.02    |
| Peak             | 2,857 (1,909–4,960)| 2,420 (1,616–3,655) | 3,398 (2,376–8,537) | 0.00    |
| Prior to CTPA    | 1,809 (901–3,199)| 1,532 (779–2,560) | 2,381 (1,495–4,774) | 0.00    |
| Ferritin, ng/mL  |               |                 |             |         |
| Baseline         | 711 (349–1,226)| 764 (339–1,453) | 628 (366–1,046) | 0.36    |
| Peak             | 872 (723–1,050)| 881 (710–1,052) | 864 (744–1,049) | 0.94    |
| Prior to CTPA    | 720 (354–1,313)| 752 (388–1,462) | 643 (349–1,110) | 0.28    |
| D-dimer-to-ferritin ratio |     |                 |             |         |
| Baseline         | 1.2 (0.3–3.8) | 1 (0.3–2.1)     | 1.8 (0.4–12.5) | 0.03    |
| Peak             | 4.9 (2–10.2)  | 3.7 (1.9–8.8)   | 5.4 (2.6–12.5) | 0.05    |
| Prior to CTPA    | 2.3 (0.9–7.1) | 1.8 (0.8–5.1)   | 3.4 (1.7–10.6) | 0.03    |
| D-dimer-to-LDH ratio |          |                 |             |         |
| Baseline         | 1.9 (0.8–6.8) | 1.6 (0.7–4.4)   | 2.8 (0.9–11.8) | 0.01    |
| Peak             | 7.6 (4.6–11.9)| 6.7 (5.9–10.9)  | 8.3 (6.1–16.9) | 0.01    |
| Prior to CTPA    | 5 (2.6–8.9)   | 3.5 (2.1–7.5)   | 6.3 (3.9–10.7) | 0.01    |
| D-dimer-to-CRP ratio |          |                 |             |         |
| Baseline         | 97.6 (35–364) | 82.3 (33.9–227.8)| 133.6 (36.3–554.6) | 0.09    |
| Peak             | 1157.3 (404.9–3905.7)| 1068.4 (404.9–3505.2) | 1230.6 (390.3–4118.9) | 0.95    |
| Prior to CTPA    | 442.4 (127.6–1474.6)| 407.8 (110.6–1310.2) | 446.3 (170.1–1602.9) | 0.49    |
| Platelet count, 10^3/µL |       |                 |             |         |
| Baseline         | 210 (169–297) | 204.5 (171–282) | 230 (164–303) | 0.54    |
| Peak             | 386 (288–495) | 397 (288–505)   | 351 (288–481) | 0.22    |
| Prior to CTPA    | 279 (198–354) | 274 (193.5–350.5)| 284 (203–371) | 0.52    |
| Lymphocyte counts |             |                 |             |         |
| Baseline,%       | 13.5 (8.5–19.7)| 14.3 (8.4–20.5) | 11 (7.7–15.9) | 0.03    |
| Peak, %          | 7 (4.5–12.2)  | 8.2 (4.7–13.6)  | 5.8 (3.7–9)  | 0.03    |
| Prior to CTPA,%  | 15.9 (10.2–25.9)| 18.3 (11.8–28.8)| 13.2 (7.9–19.8) | 0.00    |
| NLR              |               |                 |             |         |
| Baseline         | 5.8 (3.7–10.1)| 5.2 (3.4–8.8)   | 7.2 (4.6–10.7) | 0.02    |
| Peak             | 12.4 (6.8–20.1)| 10.6 (5.8–19)  | 15 (9.7–24.9) | 0.02    |
| Prior to CTPA    | 4.7 (2.5–8.1) | 4.1 (2.2–6.9)   | 5.5 (3.5–10.2) | 0.00    |
| PDW,%            |               |                 |             |         |
| Baseline         | 16.3 (15.8–16.8)| 16.1 (15.7–16.8)| 16.6 (16.1–17.2) | 0.00    |
| Peak             | 17.2 (16.9–17.9)| 17.1 (16.8–17.7)| 17.3 (16.9–18.2) | 0.04    |
| Prior to CTPA    | 16.4 (15.9–16.8)| 16.2 (15.8–16.7)| 16.6 (16.1–16.9) | 0.01    |
| IL-6, pg/mL peak | 62.5 (23–181) | 60.4 (19.6–19.5) | 64 (31–140) | 0.77    |
The model explained 39.1% (Nagelkerke $R^2$) of the variance. HL was 0.942, confirming an appropriate goodness-of-fit.

### DISCUSSION

To the best of our knowledge, this is the largest prospective study to date systematically exploring the real incidence of PE in a cohort of patients with COVID-19 admitted to a hospital. Additionally, taking several variables together, our study enabled us to develop a PE score that could be used as a prediction rule for this population, once adequately validated.

### Previous Studies

The increased risk of PE in COVID-19 has been described previously, yet with a high variability of reported rates (7, 8, 22–24) and contradictory data (15, 16). The true incidence of PE is not clear, since diagnostic tests were mostly performed (7, 8, 22–24) and contradictory data (15, 16). The true incidence of PE was increased approximately 2–3-fold during the first 2 weeks in hospitalized patients with COVID-19, showing the incidence in all patients at the time of hospital admission regardless of COVID-19 severity or D-dimer value (9). In addition, there was a 15-day median interval between symptom onset and CTPA in our study, which is longer than the 7 days in the latter study. Remarkably, recent data found that the incidence of PE was increased approximately 2–3-fold during the first 2 weeks in hospitalized patients with COVID-19, supporting the hypothesis of a delayed procoagulant state throughout the second phase of the disease following the cytokine storm (30).

### D-Dimer and Other Potential Biomarkers of Pulmonary Embolism in COVID-19

Relationships between COVID-19 and PE are very complex, with many factors and confounding variables yet to be clarified. D-dimer, a degradation product of cross-linked fibrin, is considered to reflect the global activity of clot formation and lysis, and increased levels have been correlated with COVID-19 severity (2–5). In addition, D-dimer levels have been found to be higher in COVID-19 patients with PE (7, 9–11, 22, 23). However, confusion regarding the type of DDUs, either as DDU or fibrinogen equivalent units (FEU), can create incorrect conclusions, as the FEU value is two times that of DDU, and...
some of the abovementioned studies did not report any DDU (9, 10, 13, 31). Further studies should harmonize D-dimer levels so as to ensure the comparability of different assays (32). In the present study, all the patients included presented D-dimer > 1,000 ng/mL, but patients with PE showed even higher values than non-PE subjects. Further, it is worth noting that, despite inflammation biomarkers being equally high in both groups, there were significant differences in D-dimer-to-ferritin and D-dimer-to-LDH ratios, with both proving to be higher in the PE group. Moreover, other biomarkers, such as PDW and NLR, were significantly higher in patients with PE as compared to patients without PE. Interestingly, both PDW and NLR have also been described as severity markers in COVID-19 (33, 34), with more increased NLR among PE cases (35). Higher PDW, a surrogate marker of platelet activation, has also been found in non-COVID-19 PE patients (36). This whole scenario with higher D-dimer, NLR, and PDW values in patients with PE, together with the fact that deep vein thrombosis (DVT) is uncommon in hospitalized COVID-19 individuals (37, 38), supports the hypothesis that SARS-CoV-2 could induce direct alveolar damage, promoting a local immunothrombosis phenomenon in the pulmonary arteries.

Clinical Implications
Retrospective data showed that PE is associated with both increased mortality and length of hospital stay in patients with COVID-19 (13, 23). By contrast, we found no significant differences in clinical outcomes when comparing patients with PE to patients with non-PE, which may be due to a notable influence of early detection and a prompt start of anticoagulant treatment (39). However, since thrombi were mainly peripheral with a low overall thrombotic load, they could have had a minor influence on clinical outcomes. Our results, however, are in accordance with other prospective studies (9, 10). Nonetheless, the sample size of the present study may not be sufficiently powered to find differences in these objectives.

In our study, as in most of the abovementioned ones, PE incidence was high despite much of the population being on anticoagulant thromboprophylaxis. Recent randomized trials showed that full anticoagulation with heparin may be clinically favorable in COVID-19 (39, 40), raising uncertainties about the
was routinely performed in patients with D-dimer > 1,000 ng/mL; therefore, the usefulness of the PATCOM score and the incidence of PE among the remaining patients with SARS-CoV-2 pneumonia are unknown.

CONCLUSION

In conclusion, we have demonstrated a very high incidence (39.7%) of PE in consecutively admitted COVID-19 patients with pneumonia and D-dimer values > 1,000 ng/mL, regardless of clinical suspicion. Further, patients with PE had higher D-dimer levels both in absolute terms and relative to systemic inflammation biomarkers and significant differences in PDW, NLR, and lymphocyte count. In addition, patients with PE required higher O2 concentrations, although no differences in clinical outcomes were found. Our findings could be relevant to the management of these patients and could help in clinical decision-making, such as performing CTPA or starting empirical anticoagulation. We have developed the 4-variable PATCOM score as a promising easy prediction PE rule, which needs to be further validated.

DATA AVAILABILITY STATEMENT

Due to the applicable privacy regulation and Good Clinical Practices legislation, the full underlying dataset supporting the study cannot be provided. This dataset contains potentially identifying information, for example, age, BMI, and data of admission to the hospital leading to a unique subject in the dataset. Moreover, sharing individual participant data with third parties was not specifically included in the informed consent form of the study, and unrestricted diffusion of such data may pose a potential threat of revealing participants' identities, as permanent data anonymization was not carried out. However, other researchers who meet the criteria for access to confidential data may request to gain access to the minimal data set under the results under request at the Ethics Committee (contact via: https://www.caib.es/sites/comiteetic/es/portada44578/?campas=yes) (e-mail address: ceic_ib@caib.es). Besides, the researchers shall submit a methodological proposal.

ETHICS STATEMENT

The Institutional Ethics Committee of the Balearic Islands approved the study (IB 4197/20 PI), and all subjects gave their written informed consent. Only patients with a critical clinical condition gave verbal consent instead, in front of at least two witnesses.

AUTHOR CONTRIBUTIONS

CS, AA-F, ES-L, NT-P, and JS conceptualized, administered, and supervised the study. AA-F designed the study protocol with the help of NT-P. AA-F analyzed the data. AA-F and BN were responsibility for funding acquisition. NC, LR-C, JM, SH, DM-G, JB, and LM contributed to patient recruitment and data collection. AA-F attested that all listed authors meet authorship criteria. All authors were involved in further drafts of the manuscript and revised it critically for content and approved the final version of the manuscript.

FUNDING

This work was supported by IdISBa COVID-19/22, and Programa “Ramon Llull,” contractes per a la Intensificació de l’Activitat Investigadora a l’IdISBa 2020. This study received funding from
Bohringer-Ingelheim. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

ACKNOWLEDGMENTS

We thank all the patients and their families for their willingness to participate in the study. We are grateful to the many front-line healthcare staff for their dedication when faced with this outbreak, despite the potential threat to their own lives and the lives of their families. We also thank M. M. Amengual Salas and Meryl Jones for their language assistance and the Methodological and Statistical Support Platform of IdiSba.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.936816/full#supplementary-material

REFERENCES

1. Ioannidou JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. (2021) 51:e13554. doi: 10.1111/eci.13554
2. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. (2020) 369:m1966. doi: 10.1136/bmj.m1966
3. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/nejmoa2002032
4. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. (2020) 35:1123–38. doi: 10.1007/s10654-020-00699-1
5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemostasis. (2020) 18:844–7. doi: 10.1111/jth.14768
6. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced Pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. (2020) 19:102537. doi: 10.1016/j.autrev.2020.102537
7. Bellmunt-Montoya S, Riera C, Gil D, Rodriguez M, Garcia-Reyes M, Martinez-Carnovale L, et al. COVID-19 infection in critically ill patients carries a high risk of venous thrombo-embolism. Eur J Vasc Endovasc Surg. (2021) 61:628–34. doi: 10.1016/j.ejvs.2020.12.015
8. Bilaloglu S, Aphinyanaphongs Y, Jones S, Itrutter E, Hochman J, Berry JS. Thrombosis in hospitalized patients with COVID-19 in a New York city health system. JAMA J Am Med Assoc. (2020) 324:799–801. doi: 10.1001/jama.2020.13372
9. Jeunen M, Sanchez O, Chocron R, Andronikou M, Raphael M, Meyrignac O, et al. Prevalence of pulmonary embolism in patients hospitalized in time at the hospital of admission. Eur Respiratory J. (2021) 58:2100116. doi: 10.1183/13993003.00711-2021
10. Loﬁ M, Regazzoni V, Toselli M, Cereda A, Palmisano A, Vignale D, et al. Incidence and characterization of acute pulmonary embolism in patients with SARS-CoV-2 pneumonia: a multicenter Italian experience. PLoS One. (2021) 16:e0245565. doi: 10.1371/journal.pone.0245565
11. García-Ortega A, Oscullo G, Calvillo P, López-Reyes R, Méndez R, Gómez-Oliva JD, et al. Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection: pulmonary embolism in COVID-19 infection. J Infect. (2021) 82:261–9. doi: 10.1016/j.jinf.2021.01.003
12. Alonso-Fernández A, Toledo-Pons N, Cosio BG, Millán A, Calvo N, Ramón L, et al. Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-vimer levels: a prospective study. PLoS One. (2020) 15:e0238216. doi: 10.1371/journal.pone.0238216
13. Mirsadraee S, Gorog DA, Mahon CF, Rawal B, Semple TR, Nicol ED, et al. Prevalence of thrombotic complications in ICU-treated patients with coronavirus disease 2019 detected with systematic CT scanning. Crit Care Med. (2021) 49:804–15. doi: 10.1097/CCM.0000000000004890
14. Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of Intermediate-Dose vs Standard-Dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA J Am Med Assoc. (2021) 325:1620–30. doi: 10.1001/jama.2021.4152
15. Chaudhary R, Padrnos L, Wysokinska E, Pruthi R, Misra S, Sritharan M, et al. Macrovascular thrombotic events in a mayo clinic enterprise-wide sample of hospitalized COVID-19–Positive Compared With COVID-19–Negative patients. Mayo Clin Proc. (2021) 96:1718–26. doi: 10.1016/j.mayocp.2021.04.022
16. Gallastegui N, Zhou JY, Drygaliska A, Barnes FWW, Fernandes TM, Morris TA. Pulmonary embolism does not have an unusually high incidence among hospitalized COVID19 patients. Clin Appl Thromb Hemostas. (2021) 27:1–9. doi: 10.1177/1076029621996471
17. Colling ME, Kanthi Y. COVID-19–associated coagulopathy: an exploration of mechanisms. Vasc Med (United Kingdom). (2020) 25:471–8. doi: 10.1177/1358863X20932640
18. Konstantinides SV, Meyer G, Bueno H, Gallé N, Gibbs JSR, Ageno W, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. (2020) 41:543–603. doi: 10.1093/eurheartj/ehz005
19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
20. Han H, Yang L, Liu R, Liu F, Wu K-L, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. (2020) 58:1116–20. doi: 10.1515/cclm-2020-0188
21. Le Jeune S, Suhl J, Benainous R, Minvielle F, Purser C, Foudi F, et al. High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards. J Thromb Thrombolysis. (2021) 51:637–41. doi: 10.1007/s11239-020-02246-w
22. Scudiero F, Silviero A, di Maio M, Russo V, Citro R, Personeni D, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. (2021) 198:34–9. doi: 10.1016/j.thromres.2020.11.017
23. Whyte MB, Kelly PA, Gonzalez E, Arya R, Roberts LN. Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res. (2020) 195:95–9. doi: 10.1016/j.thromres.2020.07.025
24. Filippi L, Sartori M, Facci M, Trentin M, Armani A, Guadagnin ML, et al. Pulmonary embolism in patients with COVID-19 pneumonia: when we have to search for it? Thromb Res. (2021) 206:29–32. doi: 10.1016/j.thromres.2021.08.003
25. Jalde FC, Beckman MO, Svensson AM, Bell M, Skold M, Strand F, et al. Widespread parenchymal abnormalities and pulmonary embolism on contrast-enhanced CT predict disease severity and mortality in hospitalized COVID-19 patients. Front Med. (2021) 8:666723. doi: 10.3389/fmed.2021.666723
26. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP. Strengthening the reporting of observational studies in epidemiology
Suarez Castillejo et al. Pulmonary Embolism in COVID-19 Pneumonia

29. Wu Y-H, Gao S-H, Mei J, Xu J, Fan D-P, Zhang R-G, et al. JCS: an explainable COVID-19 diagnosis system by joint classification and segmentation. *IEEE Trans Image Proc.* (2021) 30:3113–26. doi: 10.1109/TIP.2021.3058783

30. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Jerald H, Lundevelcher EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. *BMJ.* (2022) 377:e069590. doi: 10.1136/bmj-2021-069590

31. Favaloro EJ, Thachil J. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. *Clin Chem Lab Med.* (2020) 58:1191–9. doi: 10.1515/cclm-2020-0573

32. García de Guadiana-Romualdo L, Morell-Garcia D, Favaloro EJ, Vilchez JA, Bautza JM, Alcaide Martin MJ, et al. Harmonized D-dimer levels upon admission for diagnosis of COVID-19 severity: results from a Spanish multicenter registry (BIOMOC-Spain study). *J Thromb Thrombolysis.* (2022) 53:103–12. doi: 10.1007/s11239-021-02527-y

33. Yardimci AC, Yildiz S, Ergen E, Balli H, Ergene E, Guner YS, et al. Association between platelet indices and the severity of the disease and mortality in patients with COVID-19. *Eur Rev Med Pharmacol Sci.* (2021) 25:6731–40. doi: 10.26355/eurrev_202111_27118

34. Karimi A, Shoberi P, Kulasinghe A, Rezaei N. Novel systemic inflammation markers to predict COVID-19 prognosis. *Front Immunol.* (2021) 12:741061. doi: 10.3389/fimmu.2021.741061

35. Strazzulla A, Abroug Ben Halima S, Chouchane I, Rezek M, Pinto Stebler M, Hamrouni S, et al. The predictive value of cell blood count parameters to diagnose pulmonary embolism in patients with SARS-CoV-2 infection: a case control study. *Antibiotics.* (2022) 11:60. doi: 10.3390/antibiotics11010060

36. Huang J, Chen Y, Cai Z, Chen P. Diagnostic value of platelet indexes for pulmonary embolism. *Am J Emerg Med.* (2015) 33:760–3. doi: 10.1016/j.ajem.2015.02.043

37. Kwee RM, Adams HJA, Kwee TC. Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. *Eur Radiol.* (2021) 31:8168–86. doi: 10.1007/s00330-021-08003-8

38. Fares Y, Sinzogni-Eyoum YC, Billoir P, Bogaert A, Armengol G, Alexandre K, et al. Systematic screening for a proximal DVT in COVID-19 hospitalized patients: results of a comparative study. *JMV J Med Vasc.* (2021) 46:163–70. doi: 10.1016/j.jmv.2021.05.003

39. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in non-critically ill patients with COVID-19. *N Engl J Med.* (2021) 385:790–802. doi: 10.1056/NEJMoa2105911

40. Sholzberg M, Tang GH, Rahhal H, Alhamzah M, Kreuziger LB, Áinle FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: rapid randomised clinical trial. *BMJ.* (2021) 375:n2400. doi: 10.1136/bmj.n2400

Conflict of Interest: AA-F reports personal fees from Astrazeneca, GSK, Chiesi, and Menarini, from outside the submitted work. JS reports personal fees, as a speaker, from Roche and Boehringer-Ingelheim, with no relationship with the submitted work. ES-L reports personal fees from Astrazeneca, GSK, and Boehringer-Ingelheim, personal and advisory board fees from MSD, and grants, personal, and advisory board fees from Actelion and Janssen, from outside the submitted work. BN reports personal fees from Roche, Brystol, and Boehringer-Ingelheim, with no relationship with the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Suarez Castillejo, Toledo-Pons, Calvo, Ramon-Clar, Martínez, Herreros de Mendoza, Morell-Garcia, Bauça, Berga, Naité, Preca, Saulela, Argente Castillo, Ballesteros, Martín, Sala-Llinares and Alonso-Fernández. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.